Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06256484 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Atara Biotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06256484 is a Phase 1 study that was terminated before completion, run by Atara Biotherapeutics. The registered enrollment target is 1 participants.
The verdict
NCT06256484, a Phase 1 study, was terminated before completion, sponsored by Atara Biotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).
Interventions
- DRUG ATA3219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-09-06 |
| Est. Completion | 2025-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06256484
The ClinicalTrials.gov registry entry for NCT06256484 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atara Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATA3219 is the first listed.
NCT06256484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06256484 about?
NCT06256484 is a clinical study titled "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).
What is the current status of trial NCT06256484?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-09-06. Estimated completion is 2025-03-30.
What interventions are being tested in trial NCT06256484?
The interventions under investigation include: ATA3219 (DRUG).
Who is sponsoring clinical trial NCT06256484?
This trial is sponsored by Atara Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.